Limbus AI

Regina, Saskatchewan, Canada All Canada companies → — Founded 2017

Imaging AI Specialist Specialty-Focused AI

Oncology Radiology

Oncology AI Radiology & Imaging AI

Acquired/Merged — Undisclosed (Acquired)

Claim this company

Products

Limbus Contour

Limbus AI

Oncology AI

Limbus Contour is an AI-powered automatic contouring software for radiation therapy, designed to improve efficiency and clinical workflows in cancer treatment planning by rapidly and accurately delineating anatomical structures.

Contact for pricing

See all 1 product →

About Limbus AI

Limbus AI is a healthcare AI company specializing in the development of machine learning-based software solutions for cancer radiation therapy. Their flagship product, Limbus Contour, is an AI-driven automatic contouring software designed to significantly enhance the efficiency and precision of clinical workflows in radiation treatment planning. For physicians, this translates to a substantial reduction in the time required for manual delineation of organs at risk and tumor volumes on CT and MRI scans, a process that is traditionally time-consuming and prone to inter-observer variability.

The software operates directly on existing clinical workstations, ensuring patient data security by eliminating the need for cloud transfer. Limbus Contour has received FDA 510(k) clearance and CE Mark certification, underscoring its clinical grade accuracy and utility. By automating this critical step, Limbus AI’s technology enables clinicians to create more accurate treatment plans more quickly, allowing for more precise radiation delivery and potentially increasing the capacity for patient care. The company has also formed strategic partnerships with other medical technology leaders, such as Accuray and RefleXion Medical, to integrate its advanced contouring algorithms into adaptive radiotherapy systems, further streamlining the treatment planning process and supporting personalized cancer care.

Focus Areas

Radiation oncology cancer care automated contouring treatment planning machine learning deep learning workflow efficiency

Business Intelligence

Key Investors	Cultivator
Partnerships	Accuray, RefleXion Medical, AMG Medtech UK, Medintec Latin America (Brazil), Icon Oncology (Southern Africa)
Acquisitions	Acquired by Radformation, Inc. (April 30, 2024 / May 1, 2024)
Technology	Machine learning-based software, AI-driven automatic contouring algorithms, deep learning segmentation, operates on existing clinical workstations, local network (no cloud transfer of patient data), vendor-neutral (DICOM compliant RT-Structure files)
FDA Clearances	2 cleared products (estimated)

What Physicians Need to Know

Specialization

Limbus AI specializes in advanced software solutions for radiation oncology and cancer care, primarily focusing on automated contouring and treatment planning to enhance workflow efficiency.

Automated Contouring (Limbus Contour)

Their flagship product, Limbus Contour, utilizes clinically validated deep-learning segmentation algorithms to automatically delineate tumor targets and organs at risk (OARs) on CT and MRI scans. This significantly reduces the manual contouring time, with reported reductions of up to 80% and specific examples like 26 minutes for prostate and nodes patients, and 80 minutes for head-neck tumors.

Workflow Efficiency

Limbus AI's solutions streamline the radiotherapy planning process, addressing a major bottleneck in cancer treatment. By automating contouring, they improve clinical workflows, reduce treatment delays, and allow clinicians to dedicate more time to complex planning tasks and direct patient care.

Key Differentiator: Local Installation & Data Security

A significant differentiator is that Limbus Contour operates entirely on customers' existing clinical workstations within their local network, ensuring all patient data remains secure and is not transferred to the cloud. This simplifies information governance and compliance.

Key Differentiator: Accuracy & Consistency

The software employs clinically validated deep-learning algorithms to achieve high accuracy in contouring, reducing human error and inter-observer variability often associated with manual delineation. This leads to more precise treatment plans and radiation delivery.

Technology Stack

Limbus AI's software is AI-coded and Python-based, utilizing convolution neural network algorithms and a U-net model architecture. It is trained using TensorFlow on publicly available CT datasets. GPU versions require a CUDA-capable NVIDIA GPU.

Regulatory Clearances

Limbus Contour has received FDA 510(k) clearance in the U.S. and CE Mark certification for the European market, demonstrating its compliance with stringent medical device regulations.

Physician Tip

For physicians, Limbus AI stands out by significantly reducing the time burden of manual contouring, freeing up valuable time for more complex planning, patient consultations, and direct care. The clinically validated deep-learning algorithms enhance the accuracy and consistency of contours, leading to more precise radiation delivery and potentially improved patient outcomes. The local installation model ensures robust patient data security and simplifies compliance. While Limbus AI offers substantial efficiency gains, it's crucial for physicians to maintain expert review of the AI-generated contours to ensure optimal planning and address any patient-specific anatomical nuances or potential discrepancies, as highlighted in clinical evaluations.

Limbus AI's solutions are designed for compatibility with various treatment planning systems and DICOM viewing systems. They have established key partnerships and integrations, including a licensing agreement with RefleXion Medical, Inc. to incorporate Limbus Contour into the RefleXionu00ae X1 radiotherapy treatment planning system, and a partnership with Accuray Incorporated to augment their adaptive radiotherapy capabilities. Limbus AI was acquired by Radformation in April 2024, with plans to integrate the superior features of both platforms to offer an even more advanced AI-driven contouring solution.

At a glance

Founded 2017

HQ Regina, Saskatchewan, Canada · Canada

Team size 13

CEO Dr. Karl Otto

Funding Acquired/Merged — Undisclosed (Acquired)

FDA clearances 2 (estimated)

Products 1

Products by Limbus AI

1 product in the directory

Limbus Contour

Limbus AI

Oncology AI

Contact for pricing

What the Web Says

Limbus AI appears to be a well-regarded company, particularly for its AI-driven contouring software in radiation oncology. Reviews highlight its effectiveness in improving efficiency and accuracy for clinicians. Employer reviews are less prevalent but generally positive, suggesting a good work environment.

Overall: Positive

Strengths

Significantly improves efficiency and reduces contouring time for radiation oncologists.
Enhances accuracy and consistency of treatment plans.
User-friendly interface and easy integration with existing systems.
Strong customer support and responsiveness.
Reduces inter-observer variability in contouring.
Potential for improved patient outcomes due to more precise targeting.

Limitations

Limited number of public employer reviews available.
Initial setup and integration might require some effort.
Reliance on AI may raise concerns for some clinicians regarding full control.
Specific pricing details are not readily available in public reviews.
As with any AI, potential for occasional errors or need for manual override.
May require a learning curve for new users unfamiliar with AI-assisted contouring.

Based on reviews from: G2, Glassdoor, Capterra, Healthcare IT News/Review Sites, Reddit

Last updated: 2026-07-19

Videos

News, demos, and interviews about Limbus AI.

Loading videos...

Videos load interactively. If none appear, search YouTube for Limbus AI →

View all on YouTube

Press & Coverage

Limbus AI (via Radformation)

Radformation to Accelerate AI-Based Solutions with Limbus AI Acquisition

Radformation, Inc. acquired Limbus AI on April 30, 2024, to expand its AI-driven capabilities in cancer care and enhance radiation therapy automation solutions. This merger aims to integrate the strengths of both companies' platforms to offer advanced AI-driven contouring solutions.

2024-04

RefleXion Medical, Inc.

RefleXion and Limbus AI Announce Technology Integration to Expedite Cancer Treatment Planning

RefleXion Medical Inc. and Limbus AI, Inc. announced a licensing agreement on March 28, 2024, to integrate Limbus' automated contouring software, Limbus Contour, into the RefleXion X1 radiotherapy treatment planning system. This integration is expected to significantly reduce contouring time, a major bottleneck in radiotherapy planning.

2024-03

PubMed (British Journal of Radiology)

Clinical evaluation of the efficacy of limbus artificial intelligence software to augment contouring for prostate and nodes radiotherapy

Published on May 29, 2024, this study evaluated Limbus AI's auto-contouring software for prostate radiotherapy, finding significant time savings (13-26 minutes per patient) and good geometric similarity with expert contours, making it an essential part of clinical practice.

2024-05

Limbus AI (via Accuray)

Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixactu00ae System at American Society for Radiation Oncology (ASTRO) Annual Meeting

Accuray Incorporated and Limbus AI unveiled Cenosu2122, an online adaptive therapy option for the Radixactu00ae System, at the 2023 ASTRO Annual Meeting. This solution, with a 510(k) pending, is designed to enable quick adjustments to treatment plans while the patient is on the treatment table.

2023-10

Limbus AI

Limbus AI Receives CE Mark Certification for Limbus Contour

Limbus AI received CE Mark certification for Limbus Contour, its AI-powered automatic contouring software, demonstrating compliance with European health, safety, and environmental protection standards.

2023-08

Limbus AI

Limbus AI Inc. announces full Marketing Authorization from ANVISA for Limbus Contouru2122

Limbus AI Inc. announced on August 23, 2023, that it received full Marketing Authorization from ANVISA (Brazil's National Health Surveillance Agency) for its AI auto-contouring software, Limbus Contouru2122.

2023-08

Accuray Incorporated

Accuray and Limbus AI Inc. Partner to Leverage Limbus' Innovative AI-driven Technology to Enhance Accuray Adaptive Radiotherapy Solutions

Accuray Incorporated and Limbus AI Inc. announced a partnership on June 2, 2022, to augment Accuray's adaptive radiotherapy capabilities by integrating Limbus' AI-driven autocontouring algorithms, aiming to streamline the treatment planning process.

2022-06

Limbus AI

Limbus AI announces 510(k) clearance from the U.S. Food and Drug Administration for Limbus Contour

Limbus AI announced 510(k) clearance from the U.S. FDA for Limbus Contour, its AI-powered automatic contouring software, which is designed to improve efficiency in cancer diagnosis and treatment planning.

2020-08

Frequently Asked Questions

What is Limbus AI's primary product and how does it benefit radiation oncology workflows?

Limbus AI's flagship product is Limbus Contour, an AI-powered software designed for automatic contouring in radiation therapy. It significantly enhances workflow efficiency by reducing the manual time spent delineating Organs at Risk (OARs) and target volumes, thereby allowing clinicians to focus more on complex treatment planning and direct patient care.

How does Limbus AI utilize machine learning and deep learning in its automated contouring solution?

Limbus Contour employs state-of-the-art deep learning and convolutional neural network algorithms to perform clinically validated segmentation for radiotherapy. This advanced technology enables the software to accurately and consistently delineate anatomical structures and potential tumor areas, improving precision in treatment planning.

What regulatory clearances and compliance standards does Limbus AI's software meet?

Limbus Contour has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark certification, affirming its adherence to stringent medical device regulations. Furthermore, the software operates entirely on local networks, ensuring patient data privacy and compliance with regulations like GDPR.

Can Limbus AI's software integrate with existing treatment planning systems, and what are its key partnerships?

Yes, Limbus Contour is designed for vendor-neutrality, exporting DICOM compliant RT-Structure files that are compatible with various existing treatment planning systems. Limbus AI has formed strategic partnerships with companies such as Accuray and RefleXion Medical to integrate its autocontouring capabilities into their adaptive radiotherapy solutions, streamlining the overall treatment planning process.

What are the typical workflow efficiency gains a healthcare facility can expect from implementing Limbus Contour?

Healthcare facilities can anticipate substantial improvements in workflow efficiency, with reported reductions in contouring time of up to 80%. This automation allows for scans to be contoured in mere seconds, significantly accelerating the dosimetry process and enabling patients to begin their radiation treatment sooner.

What is Limbus AI's current company status and how does it ensure stability for its cancer care solutions?

Limbus AI was acquired by Radformation, Inc., a prominent leader in automation solutions for cancer care, on May 1, 2024. Operating as a subsidiary, this acquisition aims to combine the strengths of both entities, fostering accelerated innovation and expanding the global reach of AI-driven solutions in radiation therapy.

How is Limbus AI's product typically priced, and what kind of customer support is available?

While specific pricing details are not publicly disclosed, Limbus AI generally operates on a subscription model with customized quotes tailored to the size and specific needs of the healthcare provider. Their privacy policy also indicates usage-based billing, such as per contoured patient. Limbus AI provides customer support for technical issues and maintains a vulnerability disclosure policy, underscoring its commitment to security and user assistance.

Related Companies

Suggest an Edit →